Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary, Holding
- Established
- 2017-12-07
- Employees
- -
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd
- Target Recruit Count
- 300
- Registration Number
- NCT06241898
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd
- Target Recruit Count
- 288
- Registration Number
- NCT05217693
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, China
🇨🇳First affiliated hospital of Gannan medical university, Ganzhou, China
A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors
Phase 1
Completed
- Conditions
- Locally Advanced/Metastatic HER2 Positive Solid Tumors
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd
- Target Recruit Count
- 117
- Registration Number
- NCT04257110
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Sarah Cannon Research, Nashville, Tennessee, United States
🇺🇸The Regents of NEXT Virginia, LLC, Fairfax, Virginia, United States
News
No news found